Sinovac Biotech, Ltd. (NASDAQ:SVA)

Monday, June 15, 2020 | Web News
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)...
Thursday, June 11, 2020 | Web News
Sinovac Biotech Ltd., ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China,...
Wednesday, May 6, 2020 | Web News
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced...
See All Research...
Wednesday, December 21, 2016, 9:29 AM
Sinovac Biotech: Court Documents Show CEO Bribed Chinese FDA, Buyout Offers Could Be in Jeopardy
See All Articles and Reports...

Sinovac Biotech Ltd. is a leading China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM)(H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.

Reverse Merger Filing

Web site: http://www.sinovac.com

Last updated April 17, 2008